The Burden of Psoriasis Across United States: Findings From the 2019 Global Burden of Diseases Study and Forecasts From 2025 to 2035

Abstract

Background. Psoriasis is a concerned public health problem across the world. Previous studies have often concentrated on the disease burden globally and in MENA areas. However, the epidemiological patterns and burden of psoriasis in the US are still lacking. This study aims to assess the incidence, prevalence, and DALYs of RA in the US between 1990 and 2019, with a pattern prediction for the next ten years addressing the lack of comprehensive research on the disease's epidemiological patterns. Moreover, correlations between incidence, prevalence, DALYs, and SDI will be examined.
 Methods. The incidence, prevalence, and DALYs in the US were investigated by age, gender, SDI, and state using the data from Global burden disease (GBD). All estimates were generated using age-standardized rates per 100,000 individuals and rate change, with 95% Uncertainty Intervals (UIs). Pearson correlation was used to analyze the relationships between incidence, prevalence, DALYs, and SDI. The forecast analysis was performed using R software, utilizing some of its packages.
 Results. The US experienced a decrease in psoriasis prevalence and incidence since 1990, with females experiencing a slightly higher decrease than men. However, US DALY rates have decreased, with males and females experiencing similar decreases. New York and Massachusetts had the highest rates, while Wyoming had the lowest. A significant positive correlation (modest power) was found between SDI and incidence, prevalence, and DALYs. The forecasting period (2025-2035) indicates that psoriasis incidence remains steady among young people of both ages, with a minor increase in elderly people. In terms of DALYs, both age groups expected a progressive decline in psoriasis.
 Conclusion. Psoriasis is still a major cause of health burden in the US with considerable differences extending between states. Updating accessible health data is required to provide more precise guidelines for the early identification and treatment of psoriasis.